Daily News

After a sharp selloff last week, NOW stock gained 6% on Monday, following a bullish note by Bernstein.

Trading of Actelis’ shares is expected to be suspended on April 10, after the company failed to meet Nasdaq’s minimum bid price requirement.

Novo said the European Medicines Agency approved transporting its blockbuster Wegovy injection at up to 30°C for up to 48 hours.

Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments.

Applied Optoelectronics has secured three major orders from hyperscale customers over the past month.

Huachen AI Parking Management’s shares have been trending lower this year, with the stock struggling to comply with Nasdaq’s $1 minimum bid requirement.

The company unveiled a platform designed to digitally track physical materials across the entire supply chain.

According to an SEC filing dated April 2, Agriculture Investment Group became the controlling shareholder of Moolec Science.

Maxson, a former executive vice president and group CFO of Schneider Electric, will replace Doug Kehring.

Shares of the company have surged after a Chinese court ruled in its favor in a patent infringement case against Apple last week.

Profusa announced plans to acquire the PanOmics diagnostic platform from BioInsights.

The study also showed discontinuation rates due to gastrointestinal events were roughly 14 times higher with orforglipron.

Following a weak February due to an extended Lunar New Year holiday, Nio, Xpeng, and Li Auto reported a strong sequential increase in vehicle deliveries for March.

The company regained compliance after the stock closed at or above $1 for at least 20 consecutive business days.

The company announced a 1-for-20 reverse stock split, effective April 6, 2026.

Novo said patients can save up to $600 per year on Wegovy pills and up to $1,200 per year on Wegovy injections with a 12-month subscription.

The biotech firm announced a deal to acquire a potential treatment for a kidney disease and secured $40 million through a private placement.

The biotech company signed a binding agreement with Allucent to support a planned Phase 2 trial to treat multiple sclerosis.

Wave Life Sciences’ interim data from the Phase 1 trial of its obesity drug showed 1% reduction in total body weight in six months, a figure that left retail investors disappointed.

The biotech firm’s Phase 1/2 trial data for its gene-editing therapy BEAM-302 showed marked improvement in patients with AAT deficiency.

The AI-based entertainment company terminated its share sale agreement with Alliance Global Partners after selling around 5.9 million shares under the deal.

AEye caught retail attention after reporting a 110% increase in fourth-quarter revenue and joining NVIDIA's Halos AI Systems Inspection Lab to boost its lidar solutions.

Teladoc Health drew investor interest following a couple of bullish brokerage actions after peer Talkspace signed an acquisition agreement with Universal Health Services a day earlier.

The Chinese EV maker reported a 76% increase in fourth-quarter revenue, beating Wall Street estimates, according to Fiscal.ai data.

MiNK Therapeutics tied up with an oncology consortium to develop a cell therapy targeting pediatric cancers.

The company announced the acquisition of a minority stake in an AI-infrastructure company in an all-stock deal.

Saudi Arabia has reportedly started cutting oil production as the escalating conflict in the Middle East saw critical energy infrastructure being targeted by both sides over the weekend.

The drone and wireless technology firm reaffirmed its 2026 revenue guidance of $170 million to $180 million.

The report states that the policy center will legalize perpetual derivatives and help regulators write DeFi guidelines for the financial system.

ARK Invest says tokenized assets could reach $11 trillion by 2030 as stablecoins, Ethereum, and institutions push finance on-chain.

Republican Congressman French Hill revealed that the market structure bill will “very soon” be on President Trump’s desk, after Republicans spent four years on it.

The JUP token is 89% below its $1.83 peak. However, the token is up 58.43% since its low.

Market-based odds now show an 87% chance of a rate cut.

Retail sentiment on SPY and QQQ stayed bearish as earnings news and after-hours swings drove action.